e-learning
resources
Virtual 2020
Pre-Congress Content
Translational therapeutic advances
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Profibrotic implication of platelet-activating factor in tuberculous pleural effusion
C. Chung (Taipei, Taiwan), M. Chen (Taipei, Taiwan), J. Tsai (Taipei, Taiwan), C. Hsieh (Taipei, Taiwan)
Source:
Virtual Congress 2020 – Translational therapeutic advances
Session:
Translational therapeutic advances
Session type:
E-poster session
Number:
3356
Disease area:
Interstitial lung diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Chung (Taipei, Taiwan), M. Chen (Taipei, Taiwan), J. Tsai (Taipei, Taiwan), C. Hsieh (Taipei, Taiwan). Profibrotic implication of platelet-activating factor in tuberculous pleural effusion. 3356
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
The role of vascular endothelial growth factor in tuberculous and parapneumonic pleural effusions
Source: Annual Congress 2008 - Pleural diseases and interventions
Year: 2008
Vascular endothelial growth factor (VEGF) in malignant and tuberculous pleural effusions
Source: Eur Respir J 2001; 18: Suppl. 33, 397s
Year: 2001
Pleural fluid interleukin-10 level in the diagnosis of tuberculous effusions
Source: Eur Respir J 2002; 20: Suppl. 38, 581s
Year: 2002
Role of C-reactive protein in discriminating complicated and uncomplicated parapneumonic effusion from malignant and tuberculous pleural effusion
Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status
Year: 2021
Neutrophil-predominant effusion as a predictive factor for outcome in tuberculous pleurisy
Source: International Congress 2018 – Pulmonary tuberculosis: long term complications, rehabilitation and challenges
Year: 2018
Diagnostic value of interleukin-12 p40 in tuberculous pleural effusions
Source: Eur Respir J 2009; 33: 816-820
Year: 2009
Interelukin-17A is elevated in parapneumonic pleural effusions and is associated with neutrophils and VEGF
Source: Eur Respir J 2006; 28: Suppl. 50, 551s
Year: 2006
Value of chitotriosidase enzyme activity in discrimination of tuberculous pleurisy from malignant pleural effusion
Source: Annual Congress 2010 - Extrapulmonary tuberculosis
Year: 2010
Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion
Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura
Year: 2012
Prognostic features of residual pleural thickening after parapneumonic pleural effusion
Source: Eur Respir J 2002; 20: Suppl. 38, 605s
Year: 2002
Tuberculous pleural effusion
Source: Eur Respir J 2003; 22: Suppl. 45, 152s
Year: 2003
Predictors of residual pleural opacity in tuberculous pleurisy
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Can VEGF be used in differential diagnosis of pleural effusions?
Source: Eur Respir J 2007; 30: Suppl. 51, 565s
Year: 2007
Diagnostic value of IL-8 in differentiating between exudative and transudative pleural effusion
Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology
Year: 2008
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012
C-reactive protein in differentiation between tuberculous and malignant pleural effusions
Source: Annual Congress 2011 - Clinical challenges in tuberculosis
Year: 2011
Talc mediates angiostasis in malignant pleural effusions via endostatin induction
Source: Eur Respir J 2007; 29: 761-769
Year: 2007
Host-derived osteopontin is important for malignant pleural effusion formation
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Osteopontin is important for malignant pleural effusion formation
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
Empyema and parapneumonic pleural effusion. Prognostic factors about 109 patients
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept